Esperite N.V., of Amsterdam, The Netherlands, which is focused on regenerative and precision medicine, said a 21st tranche of €300,000 has been issued as a private placement consisting of 30 convertible notes with a principal amount of €10,000 each, with 485,611 share subscription warrants attached. The financing was made under an agreement of up to €13 million that was signed with the European Select Growth Opportunities Fund in March last year.